Two Large Studies with New Screening Tests Show Promise for Increasing the Use of Colorectal Cancer Screening
Findings from the ECLIPSE and BLUE-C studies
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma
Evidence for efficacy is based on the results from the CheckMate 901 study
Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in Patients with Resected Stage IIB or IIC Melanoma
Findings from the final distant metastasis-free survival analysis of KEYNOTE-716 study
EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant Treatment of Resectable NSCLC
It is indicated in adult patients at high risk for recurrence
Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas
Findings from the FIRSTMAPPP study
Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Findings from the EV-302 study
FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer Indications
Evidence for efficacy is based on the results from the PAPILLON study
Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve Stage IV Colon Cancer Not Amenable for Curative Treatment
Findings from the analysis of SYNCHRONOUS and CCRe-IV studies
Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients Treated with Oral Capecitabine
Findings from the D-TORCH study
Sacituzumab Govitecan Improves Outcomes Over Single-Agent Chemotherapy in Patients with Pretreated Metastatic TNBC, Including in Subgroup Analyses
Final results from the ASCENT study
EMA Recommends Granting a Marketing Authorisation for Tislelizumab
It is intended for the treatment of patients with locally advanced or metastatic NSCLC either in monotherapy or in combination with chemotherapy
High Risk of BCSM at 20 Years in Men with Hormone Receptor Positive Stage I to III Breast Cancer
Kinetics of breast cancer specific mortality among men with higher stages of disease differ from the risk reported in women